Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals reshapes biotech M&A with $10B Crinetics acquisition
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a $10 billion all-cash deal, marking its largest acquisition to date. The transaction targets Crinetics’ commercial endocrinology pipeline, including treatments for rare metabolic disorders.
The deal follows a surge in biotech merger activity, with Crinetics’ stock surging nearly 100% after-hours on the announcement.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 15m ago.
Quick answers
Why is this deal significant for Vertex?
The $10 billion acquisition is Vertex’s largest ever, expanding its footprint in endocrinology and rare metabolic disorders through Crinetics’ commercial pipeline.
How did Crinetics’ stock react?
Crinetics’ stock surged nearly 100% after-hours following the announcement of the acquisition by Vertex.
Which sectors are most affected?
Biotech M&A activity is likely to see heightened interest, with a focus on endocrinology and rare disease therapies as key growth areas.
Coverage (5)
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms STAT · 9h ago
- Vertex to Buy Crinetics for $10 Billion in Biggest Deal Yet Bloomberg.com · 9h ago
- CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition Yahoo Finance · 9h ago
- Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion WSJ · 9h ago
- Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics Endpoints News · 9h ago
Topics
Related trends
Scientists discover an infuriating thing ovaries may start doing after menopause: study
Post-menopausal ovaries may take on unexpected roles—potentially reshaping treatments for aging and immunity
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
Ipsen’s $1.75B bid for Kartos Therapeutics reshapes blood cancer drug development—with a twist on the deal’s structure
Rabies Death: Ontario Child Dies in First Locally Acquired Case Since 1967
Medical reports reveal that an 11-year-old Ontario boy died from rabies in 2024 after a bat encounter, marking the province's first local case since 1967.
Exercise and Stress: Do High-Intensity Workouts Spike Cortisol Levels?
New reports are examining the connection between high-intensity interval training and potential spikes in cortisol levels.
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
AbbVie’s $10.9B bid for Apogee Therapeutics reshapes biotech M&A landscape overnight
GLP-1 drugs linked to boosting testosterone, sperm count in men
Emerging research links GLP-1 weight-loss medications to potential improvements in male fertility, including increased testosterone and sperm counts.